• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.

作者信息

Loscocco Giuseppe G, Antonioli Elisabetta, Romano Ilaria, Vergoni Federica, Rotunno Giada, Mannelli Francesco, Guglielmelli Paola, Vannucchi Alessandro M

机构信息

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

出版信息

Am J Hematol. 2021 Jun 1;96(6):749-754. doi: 10.1002/ajh.26153. Epub 2021 Mar 29.

DOI:10.1002/ajh.26153
PMID:33719069
Abstract
摘要

相似文献

1
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Am J Hematol. 2021 Jun 1;96(6):749-754. doi: 10.1002/ajh.26153. Epub 2021 Mar 29.
2
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.
3
Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.慢性髓性白血病、多发性骨髓瘤和慢性淋巴细胞白血病在疾病各阶段的骨髓纤维化发病率。
Bull Exp Biol Med. 2017 Feb;162(4):483-487. doi: 10.1007/s10517-017-3645-x. Epub 2017 Feb 27.
4
[CME: Multiple Myeloma - a Review].
Praxis (Bern 1994). 2018 Jul;107(14):749-754. doi: 10.1024/1661-8157/a002984.
5
When and how to treat essential thrombocythemia.何时以及如何治疗原发性血小板增多症。
N Engl J Med. 2005 Jul 7;353(1):85-6. doi: 10.1056/NEJMe058093.
6
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.高危冒烟型骨髓瘤与多发性骨髓瘤的早期检测：当前模型、治疗目标及临床意义。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.
7
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.国际预后评分系统不能准确区分原发性血小板增多症后和真性红细胞增多症后骨髓纤维化患者的不同风险类别。
Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31.
8
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.骨髓增殖性疾病（原发性血小板增多症、真性红细胞增多症、原发性巨核细胞粒细胞化生及骨髓纤维化）的诊断、发病机制与治疗
Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0.
9
Multiple myeloma following essential thrombocythemia.
Ann Biol Clin (Paris). 2013 Jul-Aug;71(4):457-60. doi: 10.1684/abc.2013.0856.
10
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.新诊断多发性骨髓瘤患者接受卡非佐米、来那度胺和地塞米松治疗的缓解率和无进展生存期：一项 2 期临床试验的 5 年随访结果。
JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457.

引用本文的文献

1
Case Report: Effects of multiple myeloma therapy on essential thrombocythemia and vice versa: a case of synchronous dual hematological malignancy.病例报告：多发性骨髓瘤治疗对原发性血小板增多症的影响及反之亦然：一例同步双血液系统恶性肿瘤病例
Front Oncol. 2023 Jun 8;13:1213942. doi: 10.3389/fonc.2023.1213942. eCollection 2023.
2
HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.2 型 CALR 突变阳性原发性血小板增多症中 HRAS 突变阳性多发性骨髓瘤：病例报告。
J Cell Mol Med. 2023 Jan;27(2):299-303. doi: 10.1111/jcmm.17647. Epub 2023 Jan 5.